Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies

Transplantation

Volumn 90, Issue 8, 2010, Pages 875-881

  Tsai, Eileen W ^a   Wallace, William D ^b   Gjertson, David W ^b   Reed, Elaine F ^b   Ettenger, Robert B ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b Division of Anatomic Pathology ^*  (United States)

Author keywords

Children; Plasma cells; Rejection; Transplant biopsies

Indexed keywords

CD20 ANTIGEN; CD4 ANTIGEN; SYNDECAN 1; CREATININE; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; B LYMPHOCYTE; CHILD; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; PLASMA CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ADOLESCENT; ALLOTRANSPLANTATION; BIOPSY; BLOOD; CADAVER; DONOR; GRAFT REJECTION; IMMUNOLOGY; INTRAOPERATIVE PERIOD; LIVING DONOR; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, CD20; B-LYMPHOCYTES; BIOPSY; CADAVER; CHILD; CHILD, PRESCHOOL; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTRAOPERATIVE PERIOD; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; RETROSPECTIVE STUDIES; SYNDECAN-1; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 78349298975     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f24e3c     Document Type: Article

References (38)

1. Sarwal M, Chua MS, Kambam N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
2. Hippen BE, Demattos A, Cook WJ, et al. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248.
3. Tsai EW, Rianthavorn P, Gjertson DW, et al. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006; 82: 1769.
4. Muorah MR, Brogan PA, Sebire NJ, et al. Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss. Pediatr Transplant 2009; 13: 217.
5. Charney DA, Nadasdy T, Lo AWH, et al. Plasma cell-rich acute renal allograft rejection. Transplantation 1999; 68: 791.
6. Meehan SM, Domer P, Josephson M, et al. The clinical and pathological implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol 2001; 32: 205.
7. Desvaux D, Le Gouvello S, Pastural M, et al. Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: High gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant 2004; 19: 933.
8. Gartner V, Eigentler T, Viebahn R. Plasma cell-rich rejection processes in renal transplantation: Morphology and prognostic relevance. Transplantation 2006; 81: 986.
9. Xu X, Shi B, Cai M, et al. A retrospective study of plasma cell infiltrates in explanted renal allografts. Transplant Proc 2008; 40: 1366.
10. Serreze DV, Silveira PA. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 2003; 6: 212.
11. Martinez-Gamboa L, Brezinschek HP, Burmester GR, et al. Immuno-pathological role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapy. Autoimmun Rev 2006; 5: 437.
12. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008; 74: 664.
13. Pescovitz M. B cells: A rational target in alloantibody-mediated solid organ transplantation rejection. Clin Transplant 2005; 20: 48.
14. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allo-grafts. Am J Transplant 2006; 6: 1560.
15. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
16. Crespo M, Pacual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
17. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
18. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
19. Colvin RB. The renal allograft biopsy. Kidney Int 1996; 50: 1069.
20. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early graft loss. Kidney Int 1993; 43: 1333.
21. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation. II. Morphology, immunopathology and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
22. Collins AB, Schneeberger E,PascualM,et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208.
23. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
24. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
25. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259.
26. Bagnasco SM, Tsai W, Rahman MH, et al. CD20-positive infiltrates in renal allograft biopsies are not associated with worse graft survival. Am J Transplant 2007; 7: 1968.
27. Einecke G, Reeve J, Mengel N, et al. Expression of B cell and immuno-globulin transcripts is a feature of inflammation in late allografts. Am J Transplant 2008; 8: 1434.
28. Tsai EW, Ettenger RB. B cells and rejection: Is there a link? Meaning and management of rejection characterized by steroid-resistance and B-cell infiltrates. Pediatric Transplant 2009; 13: 150.
29. Zarkhin V, Li L, Sarwal M. "To B or not to B?" B-cells and graft rejection. Transplantation 2008; 85: 1705.
30. Xu H, He X, Liu Q, et al. The abnormal high expression of B cell activating factor belonging to the TNF superfamily (BAFF) and its potential role in kidney transplant recipients. Cell Mol Immunol 2008; 5: 465.
31. Xu H, He X, Sun J, et al. The expression of B-cell activating factor belong to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 2009; 41: 112.
32. Steinmetz OM, Hüsken-Lange F, Turner J, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007;84: 842.
33. Edwards JC, Cambridge G. B cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394.
34. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
35. Adrogue H, Soltero L, Land G, et al. Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft. Transplantation 2006; 88: 567.
36. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747.
37. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
38. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.